Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Frexalimab vs placebo in nonrelapsing secondary progressive multiple sclerosis (SPMS)
jRCT2021240003Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in multiple sclerosis (MS) comparing Frexalimab with Placebo (2 arms). Primary endpoint: Time to onset of composite confirmed disability progression (cCDP) confirmed over 6 months. Started Nov 2024; status: active, not recruiting.
02
Drugs
frexalimab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on jRCT2021240003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021240003.